nach oben

Clinical Rheumatology

Erschienen in:

02.11.2021 | Case Based Review

Hypertrophic pachymeningitis in polyarteritis nodosa: a case-based review

verfasst von: Shun Nomura, Yasuhiro Shimojima, Yasufumi Kondo, Dai Kishida, Yoshiki Sekijima

Erschienen in: Clinical Rheumatology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Hypertrophic pachymeningitis (HP) is a rare neurological disorder with focal or diffuse thickening of the dura mater, which usually causes headache, cranial neuropathies, seizures, and motor or sensory impairments. The development of HP is attributed to an immune-mediated mechanism, and some autoimmune diseases have been implicated in the development of HP. Herein, we describe the case of a 73-year-old woman with persistent headache ascribable to HP, which developed approximately 3 years after a diagnosis of polyarteritis nodosa (PAN). She was treated with high-dose corticosteroid and cyclophosphamide that resulted in immediate disappearance of headache and improved radiological findings of thickened dura mater. In addition, she was subsequently administered methotrexate, ultimately resulting in maintenance of remission and regular reduction of prednisolone. In our review of published English articles, only two cases of HP in patients with PAN have been reported to date, suggesting that HP is a rare complication in PAN. However, it should be recognized that HP may develop as a neurological involvement related to PAN.

Hernandez-Rodriguez J, Alba MA, Prieto-Gonzalez S, Cid MC (2014) Diagnosis and classification of polyarteritis nodosa. J Autoimmun 48–49:84–89. https://doi.org/10.1016/j.jaut.2014.01.029CrossRefPubMed

Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V et al (2010) Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 62:616–626. https://doi.org/10.1002/art.27240CrossRefPubMed

Kupersmith MJ, Martin V, Heller G, Shah A, Mitnick HJ (2004) Idiopathic hypertrophic pachymeningitis. Neurology 62:686–694CrossRef

Yonekawa T, Murai H, Utsuki S, Matsushita T, Masaki K, Isobe N et al (2014) A nationwide survey of hypertrophic pachymeningitis in Japan. J Neurol Neurosurg Psychiatry 85:732–739. https://doi.org/10.1136/jnnp-2013-306410CrossRefPubMed

Song JS, Lim MK, Park BH, Park W (2005) Acute pachymeningitis mimicking subdural hematoma in a patient with polyarteritis nodosa. Rheumatol Int 25:637–640. https://doi.org/10.1007/s00296-005-0615-9CrossRefPubMed

Marie I, Hervé F, Lahaxe L, Robaday S, Gerardin E, Levesque H (2006) Intravenous immunoglobulin-associated cranial pachymeningitis. J Intern Med 260:164–167. https://doi.org/10.1111/j.1365-2796.2006.01676.xCrossRefPubMed

Shimojima Y, Kishida D, Hineno A, Yazaki M, Sekijima Y, Ikeda SI (2017) Hypertrophic pachymeningitis is a characteristic manifestation of granulomatosis with polyangiitis: a retrospective study of anti-neutrophil cytoplasmic antibody-associated vasculitis. Int J Rheum Dis 20:489–496. https://doi.org/10.1111/1756-185x.13046CrossRefPubMed

Yokoseki A, Saji E, Arakawa M, Kosaka T, Hokari M, Toyoshima Y et al (2014) Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody. Brain 137:520–536. https://doi.org/10.1093/brain/awt314CrossRefPubMed

Ikeda J, Shimojima Y, Usami Y, Ueno KI, Kishida D, Sekijima Y (2020) Cerebrospinal fluid biomarkers implicated in the pathogenesis of anti-neutrophil cytoplasmic antibody-related hypertrophic pachymeningitis. Clin Rheumatol 39:1803–1811. https://doi.org/10.1007/s10067-020-04971-2CrossRefPubMed

10.

Imafuku A, Sawa N, Kawada M, Hiramatsu R, Hasegawa E, Yamanouchi M et al (2019) Incidence and risk factors of new-onset hypertrophic pachymeningitis in patients with anti-neutrophil antibody-associated vasculitis: using logistic regression and classification tree analysis. Clin Rheumatol 38:1039–1046. https://doi.org/10.1007/s10067-018-4372-zCrossRefPubMed

11.

Sakairi T, Sakurai N, Nakasatomi M, Ikeuchi H, Kaneko Y, Maeshima A et al (2019) Hypertrophic pachymeningitis associated with antineutrophil cytoplasmic antibody-associated vasculitis: a case series of 15 patients. Scand J Rheumatol 48:218–224. https://doi.org/10.1080/03009742.2018.1498916CrossRefPubMed

12.

Kobayashi K, Nakagomi D, Furuta S, Kobayashi Y, Hanai S, Yamagata M et al (2020) Efficacy of rituximab for anti-neutrophil cytoplasmic antibody-associated hypertrophic pachymeningitis: a case series. Clin Exp Rheumatol 38(Suppl 124):176–181PubMed

13.

Nakano Y, Miyawaki Y, Sada KE, Yamamura Y, Kano Y, Hayashi K et al (2018) Development of Hypertrophic Pachymeningitis in a Patient With Antineutrophil Cytoplasmic Antibody-Negative Eosinophilic Granulomatosis With Polyangiitis. J Clin Rheumatol. https://doi.org/10.1097/rhu.0000000000000694CrossRef

14.

Lio M, Fukuda S, Maguchi S, Kawanami M, Inuyama Y (2001) Churg-Strauss syndrome with pachymeningitis refractory to steroid therapy atone–a case report. Auris Nasus Larynx 28(Suppl):S121-125. https://doi.org/10.1016/s0385-8146(01)00071-2CrossRefPubMed

15.

Shiraishi W, Tsujimoto Y, Shiraishi T (2021) Pathological findings of hypertrophic pachymeningitis associated with eosinophilic granulomatosis with polyangiitis. BMJ Case Rep 14. https://doi.org/10.1136/bcr-2021-243395

16.

Astrom KE, Lidholm SO (1963) Extensive intracranial lesions in a case of orbital non-specific granuloma combined with polyarteritis nodosa. J Clin Pathol 16:137–143. https://doi.org/10.1136/jcp.16.2.137CrossRefPubMedPubMedCentral

17.

Feringa ER, Weatherbee L (1975) Hypertrophic granulomatous cranial pachymeningitis causing progressive blindness in a chronic dialysis patient. J Neurol Neurosurg Psychiatry 38:1170–1176. https://doi.org/10.1136/jnnp.38.12.1170CrossRefPubMedPubMedCentral

18.

Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227. https://doi.org/10.1136/ard.2006.054593CrossRefPubMed

19.

Shimojima Y, Kishida D, Sekijima Y (2017) Increased BAFF and APRIL levels in the cerebrospinal fluid of patients with anti-neutrophil cytoplasmic antibody-related hypertrophic pachymeningitis. Cytokine 99:305–309. https://doi.org/10.1016/j.cyto.2017.08.013CrossRefPubMed

20.

Chen H, Zhang W, Jing J, Raza HK, Zhang Z, Zhu J et al (2019) The clinical and imaging features of hypertrophic pachymeningitis: a clinical analysis on 22 patients. Neurol Sci 40:269–274. https://doi.org/10.1007/s10072-018-3619-4CrossRefPubMed

21.

Xiao X, Fu D, Feng L (2020) Hypertrophic pachymeningitis in a Southern Chinese population: a retrospective study. Front Neurol 11:565088. https://doi.org/10.3389/fneur.2020.565088CrossRefPubMedPubMedCentral

22.

Bi Z, Shang K, Cao J, Su Z, Bu B, Xu S et al (2020) Hypertrophic pachymeningitis in chinese patients: presentation, radiological findings, and clinical course. Biomed Res Int 2020:2926419. https://doi.org/10.1155/2020/2926419CrossRefPubMedPubMedCentral

23.

De Virgilio A, de Vincentiis M, Inghilleri M, Fabrini G, Conte M, Gallo A et al (2017) Idiopathic hypertrophic pachymeningitis: an autoimmune IgG4-related disease. Immunol Res 65:386–394. https://doi.org/10.1007/s12026-016-8863-1CrossRefPubMed

24.

Lindstrom KM, Cousar JB, Lopes MB (2010) IgG4-related meningeal disease: clinico-pathological features and proposal for diagnostic criteria. Acta Neuropathol 120:765–776. https://doi.org/10.1007/s00401-010-0746-2CrossRefPubMed

25.

Seror R, Mahr A, Ramanoelina J, Pagnoux C, Cohen P, Guillevin L (2006) Central nervous system involvement in Wegener granulomatosis. Medicine (Baltimore) 85:54–65. https://doi.org/10.1097/01.md.0000200166.90373.41CrossRef

26.

Di Comite G, Bozzolo EP, Praderio L, Tresoldi M, Sabbadini MG (2006) Meningeal involvement in Wegener’s granulomatosis is associated with localized disease. Clin Exp Rheumatol 24:S60-64PubMed

27.

Tokushige S, Matsuura H, Hideyama T, Tamura K, Maekawa R, Shiio Y (2016) Hypertrophic Pachymeningitis as a Potential Cause of Headache Associated with Temporal Arteritis. Intern Med 55:523–526. https://doi.org/10.2169/internalmedicine.55.5340CrossRefPubMed

28.

Joelson E, Ruthrauff B, Ali F, Lindeman N, Sharp FR (2000) Multifocal dural enhancement associated with temporal arteritis. Arch Neurol 57:119–122. https://doi.org/10.1001/archneur.57.1.119CrossRefPubMed

29.

Marano E, D’Armiento FP, Scarano V, Tortora F, Mignogna C, Briganti F (2003) Focal hypertrophic cranial pachymeningitis associated with temporal arteritis: a new case report. J Neurol 250:98–100. https://doi.org/10.1007/s00415-003-0914-6CrossRefPubMed

30.

Cid MC, Grau JM, Casademont J, Campo E, Coll-Vinent B, Lopez-Soto A et al (1994) Immunohistochemical characterization of inflammatory cells and immunologic activation markers in muscle and nerve biopsy specimens from patients with systemic polyarteritis nodosa. Arthritis Rheum 37:1055–1061CrossRef

31.

Freire Ade L, Bertolo MB, de Pinho AJJr, Samara AM, Fernandes SR (2004) Increased serum levels of interleukin-8 in polyarteritis nodosa and Behçet’s disease. Clin Rheumatol 23:203–205. https://doi.org/10.1007/s10067-003-0851-xCrossRefPubMed

32.

De Virgilio A, Greco A, Magliulo G, Gallo A, Ruoppolo G, Conte M et al (2016) Polyarteritis nodosa: a contemporary overview. Autoimmun Rev 15:564–570. https://doi.org/10.1016/j.autrev.2016.02.015CrossRefPubMed

33.

Kikuchi K, Hoashi T, Kanazawa S, Tamaki K (2005) Angiogenic cytokines in serum and cutaneous lesions of patients with polyarteritis nodosa. J Am Acad Dermatol 53:57–61. https://doi.org/10.1016/j.jaad.2005.02.018CrossRefPubMed

34.

Sakkas LI, Bogdanos DP (2016) The role of B cells in the pathogenesis of systemic sclerosis. Isr Med Assoc J 18:516–519PubMed

35.

Yang L, Herrera J, Gilbertsen A, Xia H, Smith K, Benyumov A et al (2018) IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity. Am J Physiol Lung Cell Mol Physiol 314:L127-l136. https://doi.org/10.1152/ajplung.00200.2017CrossRefPubMed

36.

Barratt SL, Blythe T, Ourradi K, Jarrett C, Welsh GI, Bates DO et al (2018) Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF). Respir Res 19:9. https://doi.org/10.1186/s12931-017-0711-xCrossRefPubMedPubMedCentral

37.

Connolly MK, Bedrosian AS, Mallen-St Clair J, Mitchell AP, Ibrahim J, Stroud A et al (2009) In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 119:3213–3225. https://doi.org/10.1172/jci37581CrossRefPubMedPubMedCentral

Titel: Hypertrophic pachymeningitis in polyarteritis nodosa: a case-based review
verfasst von: Shun Nomura
Yasuhiro Shimojima
Yasufumi Kondo
Dai Kishida
Yoshiki Sekijima
Publikationsdatum: 02.11.2021
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 2/2022
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-021-05971-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Serum BDNF and cognitive dysfunction in SLE: findings from a cohort of 111 patients

The effectiveness of tocilizumab in treating refractory adult-onset Still’s disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response

Prevalence and factors related to sleep apnoea in ankylosing spondylitis

Body mass index trend and variability in rheumatoid arthritis

Differentiation of idiopathic pulmonary hemosiderosis from rheumatologic and autoimmune diseases causing diffuse alveolar hemorrhage: establishing a diagnostic approach